Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

β-globin Restored Autologous HSC in β-thalassemia Major Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04211480
Recruitment Status : Not yet recruiting
First Posted : December 26, 2019
Last Update Posted : December 26, 2019
Xiangya Hospital of Central South University
Information provided by (Responsible Party):
Shanghai Bioray Laboratory Inc.

Brief Summary:
This is a single center, single arm, open-label study to determine the safety and efficacy of β-globin restored autologous hematopoietic stem cells in β-thalassemia major patients with CVS-654 mutation.

Condition or disease Intervention/treatment Phase
Thalassemia Major Biological: β-globin restored autologous HSC Not Applicable

Detailed Description:
β-globin restored autologous hematopoietic stem cells will be manufactured using Crispr/Cas9 gene editing system. Subject participation for this study will be 1 year. Subjects who enroll in this study will be asked to participate in a subsequent long-term follow up study that will monitor the safety and efficacy of the treatment they receive for up to 15 years post-transplant.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: a Safety and Efficacy Study of β-globin Restored Autologous Hematopoietic Stem Cells for β-thalassemia Major Patients With CVS-654 Mutation
Estimated Study Start Date : March 1, 2020
Estimated Primary Completion Date : February 28, 2021
Estimated Study Completion Date : March 1, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Thalassemia

Arm Intervention/treatment
Experimental: β-globin restored autologous HSC
each subject will accept one dose of β-globin restored autologous hematopoietic stem cells
Biological: β-globin restored autologous HSC
gene edited autologous hematopoietic stem cells with β-globin restoration

Primary Outcome Measures :
  1. Incidence and Severity of Adverse Events as a Measure of Safety and Tolerability Adverse events assessed according to NCI-CTCAE v4.03 criteria [ Time Frame: up to 6 months post transplant ]

Secondary Outcome Measures :
  1. efficacy of β-globin restored autologous hematopoietic stem cells [ Time Frame: 12 months post transplant ]
    Independence on blood transfusion post transplant; Or, The amount of red cell transfusion in a year post transplant reduced 50% than that of the last year.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   5 Years to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 5-15 years old. Clinically diagnosed as β-thalassemia major with IVS-654 gene mutation phenotype;
  • Subjects or at least one legal guardian/agent understand and voluntarily sign informed consent.
  • Subjects with no affection with EBV, HIV, CMV, TP, HAV, HBV and HCV.
  • Subjects body condition acceptable for autologous hematopoietic stem cell transplantation.

Exclusion Criteria:

  • Subjects acceptable for allogeneic hematopoietic stem cell transplantation and have an available fully matched related donor.
  • Active bacterial, viral, or fungal infection.
  • Treated with erythropoietin prior 3 months.
  • Immediate family member with any known hematological tumor.
  • Subjects with severe psychiatric disorders to be unable to cooperate.
  • Recently diagnosed as malaria.
  • History of complex autoimmune disease.
  • Persistent aspartate transaminase (AST), alanine transaminase (ALT), or total bilirubin value >3 X the upper limit of normal (ULN).
  • Subjects with severe heart, lung and kidney diseases.
  • With serious iron overload.
  • Any other condition that would render the subject ineligible for HSCT, as determined by the attending transplant physician or Investigator.
  • Subjects who are receiving treatment from another clinical study, or have received another gene therapy.
  • Subjects or guardians had resisted the guidance of the attending doctor.
  • Subjects whom the investigators do not consider appropriate for participating in this clinical study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04211480

Layout table for location contacts
Contact: Wei Li, PhD +8618621670308

Sponsors and Collaborators
Shanghai Bioray Laboratory Inc.
Xiangya Hospital of Central South University
Layout table for investigator information
Principal Investigator: Bin Fu, Prof. Xiangya Hospital Central University

Layout table for additonal information
Responsible Party: Shanghai Bioray Laboratory Inc. Identifier: NCT04211480    
Other Study ID Numbers: 2019-BRL-00CH2
First Posted: December 26, 2019    Key Record Dates
Last Update Posted: December 26, 2019
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn